Adjunct of Immunotherapy with the Use of Tocilizumab in Critically Ill COVID-19 Improves Prognosis?: A Case Study

Abstract

A new virus named SARS CoV-2 was first identified in Wuhan, China causing a disease named as COVID-19. This emerging disease revolutionized the world completely putting a lot of burden on the healthcare system. This disease which was declared as a pandemic by World Health Organization in March, 2020 had open new gates of researches and clinical trials all over globe. The new treatment modalities identified by international organization are now paving their paths towards the use of plasma therapy and use of tocilizumab in treating COVID-19 patients. However, the recommendations are changing every day every seconds. The use of chloroquine’s (anti-malarial) which was initially under discussion is now obsoleted after receiving increasing evidences of poor outcomes in the patients. With trial and error, we are half road in finding the right therapies for COVID-19 patients.

Note: Declaration of Interest: None to declare

Funding: None to declare

Ethics: The case report was written after receiving informed consent from the guardian of the deceased patient.

Keywords: COVID-19, Immunotheraapy, Tocilizumab